Avermectin bioconversion products
US4666937A · kind A · utility
8Cited by
5References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 20, 1986 |
| Grant date | May 19, 1987 |
| Priority date | — |
| Expiry date | Feb 20, 2006 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/822
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
There are disclosed novel compounds which are derived from 22,23-dihydro avermectin Bla aglycone, 13-deoxy-22,23 dihydro overmectin Bla aglycone and 13-deoxy-22,23-dihydro overmectin Blb aglycone. The six compounds are hydroxy adducts of the substrate avermectin compound at the 12a, 24, 24a, 26, 26a and 27 positions. The hydroxy adducts are prepared by incubating the substrate with the microorganism Cunninghamella blakesleeana and isolating the hydroxy adducts from the fermentation broth. The compounds are highly potent antiparasitic, insecticidal and anthelmintic agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.